FPC Welcomes FDA Approval of AbbVie’s New Pangenotypic HCV Combination Mavyret - Hallo friend NEWS AN INSPIRATION, In the article you read this time with the title FPC Welcomes FDA Approval of AbbVie’s New Pangenotypic HCV Combination Mavyret, we have prepared well for this article you read and download the information therein. hopefully fill posts Article ECONOMY, Article HEALTH, Article POLITICS, Article SPORTS, Article TRAVELING, Article UPDATE, we write can understand. Well, happy reading.

Titre : FPC Welcomes FDA Approval of AbbVie’s New Pangenotypic HCV Combination Mavyret
link : FPC Welcomes FDA Approval of AbbVie’s New Pangenotypic HCV Combination Mavyret

FPC Welcomes FDA Approval of AbbVie’s New Pangenotypic HCV Combination Mavyret

FPC Welcomes FDA Approval of AbbVie’s New Pangenotypic HCV Combination Mavyret

Wholesale Acquisition Cost price of $26,400 for eight-week course marks significant departure from prohibitive drug prices set for first-generation cures.

NEW YORK, NY, AUGUST 4, 2017  – The Fair Pricing Coalition (FPC) today applauded U.S. Food and Drug Administration approval of the first eight-week pangenotypic, ribavirin-free, curative regimen for hepatitis C virus (HCV) infection and expressed its appreciation for a wholesale acquisition cost (WAC) that should translate into improved affordability, with fewer access restrictions, to insurers and people living with the virus.
“This is very good news for people living with HCV in the United States,” said Tim Horn, co-chair of the Fair Pricing Coalition. “The majority of people using Mavyret will be able to complete treatment in just eight weeks, compared with standard 12-week courses, depending on their treatment history and cirrhosis status.  The favorable U.S. launch price set by AbbVie should also be good news to public and private payors, resulting in fewer access barriers, a substantial increase in the number of cures, and significant progress toward HCV elimination. FPC remains committed to ensuring access the U.S. and, globally, working with its partners toward affordable pricing in low- and middle-income countries.”
Continue reading.....

Thus articles FPC Welcomes FDA Approval of AbbVie’s New Pangenotypic HCV Combination Mavyret

that is all articles FPC Welcomes FDA Approval of AbbVie’s New Pangenotypic HCV Combination Mavyret This time, hopefully can provide benefits to you all. Okay, see you in another article post.

You are now reading the article FPC Welcomes FDA Approval of AbbVie’s New Pangenotypic HCV Combination Mavyret the link address https://newsaninpiration.blogspot.com/2017/08/fpc-welcomes-fda-approval-of-abbvies.html

Tweet

Subscribe to receive free email updates: